Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 251 Ballardvale St WILMINGTON MA 01887 |
Tel: | N/A |
Website: | https://www.criver.com |
IR: | See website |
Key People | ||
James C. Foster Chairman of the Board, President, Chief Executive Officer | Flavia H. Pease Chief Financial Officer, Corporate Executive Vice President | Birgit Girshick Chief Operating Officer, Corporate Executive Vice President |
Victoria L. Creamer Corporate Executive Vice President and Chief People Officer | William D. Barbo Executive Vice President, Strategic Advisor | Joseph W. LaPlume Corporate Executive Vice President - Corporate Development and Strategy |
Shannon M. Parisotto Corporate Executive Vice President - Discovery and Safety Assessment Management | Kristen Eisenhauer Senior Vice President, Chief Commercial Officer |
Business Overview |
Charles River Laboratories International, Inc. provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and academic institutions around the globe accelerate their research and drug development efforts. The Company's Research Models and Services segment is comprised of three businesses that provide foundational tools that enables its clients to discover new molecules: Research Models, Research Model Services, and Cell Solutions. Its Discovery and Safety Assessment segment provides regulated and non-regulated DSA services to support the research, development, and regulatory-required safety testing of potential new drugs, including therapeutic discovery and optimization plus in vitro and in vivo studies, laboratory support services, and strategic non-clinical consulting and program management to support product development. Its Manufacturing Solutions segment includes Microbial Solutions and Biologics Solutions. |
Financial Overview |
For the three months ended 30 March 2024, Charles River Lbrtrs ntrntl Inc revenues decreased 2% to $1.01B. Net income decreased 35% to $67.3M. Revenues reflect Discovery And Safety Assessment segment decrease of 9% to $605.5M, United States segment decrease of 7% to $562.3M, Canada segment decrease of less than 1% to $110.4M. Net income also reflects Discovery And Safety Assessment segment income decrease of 33% to $114.8M. |